Is Investing in Moderna Stock (NASDAQ:MRNA) Simply Dead Money?
Moderna (MRNA) stock has fallen 71% over the last six months. While there’s still potential for near-term revenue tailwinds in the form of emerging infectious diseases, I’m concerned that the company may never deliver on its pipeline potential. One reason for this is the company’s extraordinary cash burn, and another is that these formative loss-making years may be negatively impacted by changing federal policy with a vaccine skeptic taking to the Department of Health and Human Services.
» Read more about: Is Investing in Moderna Stock (NASDAQ:MRNA) Simply Dead Money? »